Vaccine News and Research

Latest Vaccine News and Research

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

Bill Gates argues the case for polio eradication and expanded childhood immunization

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, argues the case for polio eradication and expanded childhood immunization in his third annual letter released today. The letter, a personal account of his priorities, also calls on governments to invest in foreign aid, even in the face of a tough economic climate.

1 Feb 2011

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it had granted multiple licenses to generic drug manufacturers "to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.

1 Feb 2011

Current prevention efforts delay but do not prevent HCV among injection drug users

A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection. The findings suggest that efforts to curb blood-borne transmission of these viral infections have had success but must be expanded against the highly transmissible HCV.

1 Feb 2011

U.K., Gates Foundation announce extra funding for global polio eradication as WEF wraps up

U.K. Prime Minister David Cameron and Bill Gates, co-chair of the Bill & Melinda Gates Foundation, on Friday at the World Economic Forum (WEF) in Davos, Switzerland, announced "extra financing for polio eradication, easing a shortfall in funding that hinders a global effort to stop the crippling virus," Bloomberg reports.

1 Feb 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce that the first group of patients receiving the lowest dose of SCIB1 in the Phase I clinical trial has been evaluated by the Cohort Review Committee.

31 Jan 2011

Research shows nestin regulates formation of neuromuscular junction

In a study published in the Jan. 30, 2011, advance online edition of Nature Neuroscience, Salk Institute of Biological Studies investigators led by Kuo-Fen Lee, PhD., show that nestin has reason for being in a completely different cell type--muscle tissue.

30 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell.

29 Jan 2011

ISU researchers study parasites that cause NTDs in humans

Richard Martin, DVM, PhD, a biomedical sciences professor at Iowa State University's College of Veterinary Medicine, has devoted his 35-year career to studying nematode parasites. These parasites infect approximately one-quarter of the world population, producing debilitating symptoms that devastate the lives and economies of many of the world's underdeveloped and impoverished areas.

29 Jan 2011

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

Despite penicillin and the dozens of antibiotics that followed it, streptococcus bacteria have remained a major threat to health throughout the world. The reason: the superb evolutionary skills of this pathogen to rapidly alter its genetic makeup.

29 Jan 2011

BMJ News reports on calls for WHO to control, prevent spread of cholera

BMJ News examines the growing pressure on the WHO to control and prevent the spread of cholera following the ongoing outbreak of the disease in Haiti.

29 Jan 2011

Research roundup: Barriers to trauma care, immunizations; Small business tax credit; Medicare coverage of preventive care

Possible Geographical Barriers To Trauma Center Access For Vulnerable Patients In The United States - This study analyzes disparities in geographic access to trauma centers in 2005, drawing from data from the 2005 American Hospital Association annual survey.

29 Jan 2011

UK government, Bill & Melinda Gates Foundation to support efforts to stamp out polio

British Prime Minister David Cameron said today that the United Kingdom would double its current contribution to polio eradication.

29 Jan 2011

Recent releases in Global Health

Innovative Health Financing Can Benefit Global Health, Pharma: "The launch of pneumococcal vaccination in Nicaragua under AMC [advance market commitment] has shown that innovative approaches to health financing can benefit both global health and pharmaceutical companies," according to a Lancet Infectious Diseases editorial that describes how the roll-out of GAVI initiative is helping to provide developing countries with low-cost pneumococcal vaccines.

28 Jan 2011

Connectome remains dynamic during development, says Scripps Research

Connected highways of nerve cells carry information to and from different areas of the brain and the rest of the nervous system. Scientists are trying to draw a complete atlas of these connections-sometimes referred to as the "connectome"-to gain a better understanding of how the brain functions in health and disease.

28 Jan 2011

Vaccine News and Research

Latest Vaccine News and Research

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Bill Gates argues the case for polio eradication and expanded childhood immunization

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Current prevention efforts delay but do not prevent HCV among injection drug users

U.K., Gates Foundation announce extra funding for global polio eradication as WEF wraps up

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Research shows nestin regulates formation of neuromuscular junction

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

ISU researchers study parasites that cause NTDs in humans

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

BMJ News reports on calls for WHO to control, prevent spread of cholera

Research roundup: Barriers to trauma care, immunizations; Small business tax credit; Medicare coverage of preventive care

UK government, Bill & Melinda Gates Foundation to support efforts to stamp out polio

Recent releases in Global Health

Connectome remains dynamic during development, says Scripps Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in